Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from TuHURA Biosciences ( (HURA) ) is now available.
On June 23, 2025, TuHURA Biosciences‘ stockholders approved an amendment to increase the company’s authorized common stock from 75 million to 200 million shares. This strategic move, formalized through a Certificate of Amendment filed with the Nevada Secretary of State, aims to enhance the company’s capital structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HURA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Nevada-based company operating in the biosciences industry, focusing on the development and commercialization of innovative biotechnological solutions.
Average Trading Volume: 175,799
Technical Sentiment Signal: Sell
Current Market Cap: $97.41M
Learn more about HURA stock on TipRanks’ Stock Analysis page.